NY-VECTORMAX
16.6.2020 15:19:11 CEST | Business Wire | Press release
IENTC Telecomunicaciones , an internet and television service provider operating in the Mexican market, today announced it is launching VectorMax’s turn-key IPTV Platform as the software to support its new television product. Serving the market for more than 10 years, IENTC Telecomunicaciones’ new service augmenting its consumer offering reflects the growing shift from broadcast television to IP delivery of live linear TV.
This marks the first commercial deployment of an all software solution enabling operators to transition from broadcast to online delivery of live linear television without having to upgrade their network architecture. The software leverages $73M of R&D from teams out of MIT, IBM Labs, Bell Labs, DARPA and MPEG related projects to deliver multicast live linear as a turn-key, fully integrated, multicast software platform for cable operators, telcos, and high-speed access providers.
“Operators need to transition and support their entertainment experiences to remain relevant and competitive,” said Peter von Schlossberg, VectorMax’s President Global Product. “Our operators are searching for solutions to deliver a live linear consumer experience side-by-side with SVOD offerings from Netflix, Hulu, Amazon, Google, etc. VectorMax developed a unique software solution that capitalizes on existing infrastructure and networks to deliver high-quality live linear broadcast & other IP services.
“Transitioning to online delivery of live linear can be daunting, but VectorMax’s software platform allowed us to quickly see our consumer offering ingested and delivered in multicast by the VectorMax software. Our own branded Streaming Media Player apps on Amazon FireTV, Roku, Android STBs, Smart TVs and iOS were live within weeks. VectorMax’s ‘show-me’ sales strategy enabled us to easily determine they were the best fit to support the growing demands of our customers,” said Carlos Arguimbau, CEO of IENTC.
VectorMax’s ability to execute technological and marketing solutions with minimal disruption to our existing operations assured us that they were an important resource to navigate new market dynamics. The end product is a win-win for both IENTC and our customers,” said Arguimbau.
IENTC’s new +TV service is bolstered by a recent study from Hub Entertainment Research. The study found that the average number of television services accessed online per viewer in the US in the past 24 months reflected a rise of over 50%. That number is expected to trend globally. IENTC is also tracking the Hub findings reflecting pay-TV subscribers who have used an operator provided set-top box to watch streaming services tend to keep using it; 58% do so to access Netflix, 61% for Amazon, and 57% for Hulu.
“These findings are a key validation of providers’ efforts to aggregate streaming services as another way to create value in the set-top box and reduce cord-cutting”, said von Schlossberg.“VectorMax deployed our Platform in December which is now being expanded to a wider area of IENTC’s footprint in Mexico. Strategically, we are positioned to help cable companies and telecoms address this shift and to market new services as easily as flicking on a switch. The VectorMax Platform is slated for a roll-out to additional customers starting Q3 2020”.
About VectorMax Corporation
VectorMax’s pioneering of technologies that increase the efficiencies in delivering IP video over large scale, fully developed, and imperfect networks, solves the evolution of live linear broadcast television to on-network online delivery. The Company holds 102 worldwide patents grounded in software-based IP transport delivery technologies.
Supported with $73 million of R&D and twelve years of intensive research and development, conducted by a development team with MIT, IBM Labs, Bell Labs, DARPA & MPEG credentials, the Company delivers a complete end to end platform comprised of multiple modules designed to work together to deliver IPTV to large scale audiences over less than optimal networks within bandwidth constrained and limited infrastructure environments. The carrier requires no other third-party component to ingest, encode, manage and deliver the immersive experience that 2020 subscribers expect. Discover more at www.vectormax.com .
About IENTC Telecomunicaciones
IENTC Telecomunicaciones is a company with more than 10 years in the telecommunications industry located in the central zone of Mexico. With high-speed internet that is offered through its’ own fiber-optic network, providing best in class service and a customer experience that guarantees business is always connected. IENTC has the most advanced technology available in the market, which enables the offering of additional services such as Mobile phone, Virtual PBX, Smart Internet, and Television services among others. Discover more at ientc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom